Matinas BioPharma FY23 EPS $(0.11) Vs $(0.10) YoY
Matinas BioPharma FY23 EPS $(0.11) Vs $(0.10) YoY
2023 Financial Results
2023 年财务业绩
Revenue for 2023 was $1.1 million, which was generated from the Company's research collaborations with BioNTech SE and Genentech Inc. This compares with revenue for 2022 of $3.2 million, which was generated from the Company's research collaboration with BioNTech SE.
2023年的收入为110万美元，来自公司与BioNTech SE和基因泰克公司的研究合作，而2022年的收入为320万美元，这来自公司与BioNTech SE的研究合作。
Total costs and expenses for 2023 were $24.9 million compared with $27.8 million for 2022. The decrease was primarily due to lower clinical trial expenses and lower professional and consulting fees. Income from selling unused New Jersey net operating losses (NOLs) and research and development tax credits was $0.5 million and $3.5 million for 2023 and 2022, respectively.
2023年的总成本和支出为2490万美元，而2022年为2780万美元。下降的主要原因是临床试验费用减少以及专业和咨询费用降低。2023年和2022年，出售未使用的新泽西州净营业亏损（NOL）和研发税收抵免的收入分别为50万美元和350万美元。
The net loss for 2023 was $22.9 million, or $0.11 per share, compared with a net loss for 2022 of $21.0 million, or $0.10 per share.
2023年的净亏损为2,290万美元，合每股亏损0.11美元，而2022年的净亏损为2,100万美元，合每股亏损0.10美元。
Cash, cash equivalents and marketable securities as of December 31, 2023 were $13.8 million compared with $28.8 million as of December 31, 2022. Based on current projections, the Company believes its cash position is sufficient to fund planned operations through the third quarter of 2024.
截至2023年12月31日，现金、现金等价物和有价证券为1,380万美元，而截至2022年12月31日为2,880万美元。根据目前的预测，该公司认为其现金状况足以为2024年第三季度的计划运营提供资金。